• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

O-058 PPODA as a mechanically stable and biocompatible coating for endovascular stents and flow diverters
ConclusionPPODA polymer coatings can improve biocompatibility and prevent thrombosis on FDs and stents by pre-coating wires for braiding or post-coating laser-cut stent devices. Future work will compare coating integrity and biocompatibility to established devices (i.e Pipeline Shield® and Fred-X®). Materials like PPODA may provide FDs and stents with a mechanically stable scaffold coating that promotes continuous re-endothelialization over an aneurysm neck, which can eliminate thrombosis and reduce recanalization rates.Abstract O-058 Figure 1SH-PEG-Silane and PPODA bound to a nitinol wire surface. Figure la is an ...
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Robertson, S., Merritt, W., Becker, T., Ducruet, A. Tags: SNIS 20th annual meeting oral abstracts Source Type: research

Natalizumab reduces ms relapse rates in uk top patients
Conclusions Notwithstanding the inherent limitations of this small-cohort analysis, natalizumab reduces relapse rate post IFN or GA. Supported by Biogen. Disclosures: RN: grant and conference travel support from Biogen; JH: employee of and holds stock/stock options in Biogen.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Nicholas, R., Hanna, J. Tags: Immunology (including allergy), Infection (neurology), Multiple sclerosis ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Reduced ms relapse rates with natalizumab: top uk cohort
Conclusions UK TOP patients exhibited ≥83.5% reduction in ARR with ≥6 months of natalizumab treatment regardless of prior therapy, a reduction maintained over ≥3.5 years with no waning of effect. Relapses resulting in hospitalisation or steroid treatment were significantly reduced post natalizumab therapy initiation. Sponsored by Biogen Idec Ltd. Disclosures: RN: grant and conference travel support from Biogen Idec Ltd. RB: employee of Biogen Idec Ltd.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Nicholas, R., Berry, R. Tags: Immunology (including allergy), Multiple sclerosis Thur 21, Parallel session 5: Therapeutics Source Type: research

Changing face of multiple sclerosis in the united kingdom 1990-2010. an incidence and prevalence study
This study was funded by a grant from the Multiple Sclerosis National Therapy Centres.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2013 Category: Neurosurgery Authors: Mackenzie, I. S., Morant, S. V., Bloomfield, G. A., MacDonald, T. M., O'Riordan, J. I. Tags: Immunology (including allergy), Multiple sclerosis Association of British Neurologists (ABN) joint meeting with the Royal College of Physicians (RCP), London, 23-24 October 2013 Source Type: research